Phase IIb/III ALLEGRO trial of ritlecitinib in alopecia areata meets primary efficacy endpoint Aug. 4, 2021
Phase I/II trial cleared to begin in Singapore with ARCT-154 and ARCT-165 for SARS-CoV-2 Aug. 4, 2021
Phase IIb study of eliapixant in refractory chronic cough meets primary efficacy outcome Aug. 4, 2021
U.S. phase II dosing begins with LUT-014 to reduce EGFR inhibitor-induced acneiform lesions Aug. 4, 2021
RSS